• Bookmark and Share

Zimbabwe Researcher Wins EMPOWER Award

Last Updated on Monday, October 24, 2016

Collaboration Advances Preeclampsia Research in Low- and Middle-Income Countries

Sao Paulo, Brazil – October 24, 2016 – Last night at the opening ceremonies of the World Congress of the International Society for the Study of Hypertension in Pregnancy (ISSHP) in Brazil, the Preeclampsia Foundation, along with its partners ISSHP and the PRE-EMPT/Global Pregnancy Collaboration (CoLab), announced the recipient of their EMPOWER Award for preeclampsia-related research.

Dr. Sarah Manyame, a physician-researcher with the Department of Obstetrics and Gynaecology at the University of Zimbabwe Parirenvatwa Group of Hospitals, was awarded $60,000 USD for her two-year project “Urine Biomarkers for Preeclampsia in High Risk Women.” Dr. James Roberts with the Magee-Womens Research Institute in Pittsburgh, Pennsylvania, will serve as Dr. Manyame’s mentor.

EMPOWER (EMpowering Progress in Obstetric and Women’s hEalth Research) was established to create partnerships between mentors and medical researchers within low- and middle-income countries to improve clinical and health services research into hypertensive disorders of pregnancy. Ninety-nine percent of maternal deaths from preeclampsia occur in low-resource settings like Zimbabwe, where 35 percent of maternal mortality is due to preeclampsia and eclampsia.

“This is the second award granted to a preeclampsia researcher from a low- to middle-income country through EMPOWER,” said Eleni Tsigas, Executive Director of the Preeclampsia Foundation. “We’re pleased to continue this program, welcoming ISSHP, PRE-EMPT/CoLab, and supporting organization New Zealand Action on Pre-eclampsia.”

With the resource constraints facing the country, Dr. Manyame said, “Zimbabwe needs a readily available, simple non-invasive test for the prediction of preeclampsia and the severity of the outcomes. Thus, this study will evaluate the preeclampsia predictive value of the Congo red Dot test, protein/creatinine ratio, calcium/creatinine ratio, PlGF/soluble Flt-1 ratio, in women at high risk and at varying stages of the disease.”

The immediate objective will be the completion of the project designed by Dr. Manyame and, when appropriate, the dissemination of the results of the study to change practice and improve care. A fundamental goal of the program is to build independent capacity for research and effective local implementation of research findings. Other objectives include developing an integrated hypertension research team, advancing the knowledge base, and supporting research operations.

Preeclampsia, the most dangerous form of pregnancy hypertension, is estimated to contribute to at least 120 maternal and 1,300 fetal or newborn deaths every day throughout the world, primarily in regions such as the Indian subcontinent, Africa, and Latin America. Most of these cases are considered preventable.


We’ll be Speaking Here


National WIC Conference

Washington, DC

March 3, 2019


GRIVAS Conference

Chillan, Chile

April 4 - 6, 2019


Lamaze Live!

Pittsburgh, Pennsylvania

April 12, 2019


AWHONN Indiana

Indianapolis, Indiana

August 23, 2019


  Invite Us to Speak at Your Event


Featured Video

What’s Happening on Twitter

preeclampsia Joint Commission, getting tough on #maternalhealth, proposes mandatory childbirth safety standards for hospitals to… https://t.co/SG3ZAUxlpp
preeclampsia This #BlackMaternalHealthWeek (April 11-17) we're proud to join @BlkMamasMatter and Black women across the U.S. to… https://t.co/FyMj3owVR4
preeclampsia @AMAGPharma CEO William Heiden makes the case for investing in women's health. As our newest Corporate Partner, AMA… https://t.co/hNyGmXkXhP

Other Resources

JOIN OUR MAILING LIST. We respect your privacy.